PDF herunterladen
Semin Thromb Hemost 2002; 28(3): 269-272
DOI: 10.1055/s-2002-32661
Copyright © 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Preclinical Pharmacology of Albumin-Free B-Domain Deleted Recombinant Factor VIII

Kenneth Brinkhous1 , Helena Sandberg2 , Lars Widlund2 , Marjorie Read1 , Timothy Nichols1 , Jeffery Sigman1 , Ulla Oswaldsson2 , Robert G. Schaub3 , Marianne Mikaelsson2
  • 1University of North Carolina, Chapel Hill, Chapel Hill, North Carolina
  • 2Pharmacia AB, Stockholm, Sweden
  • 3Wyeth Research, Cambridge, Massachusetts
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
04. Juli 2002 (online)

    Lizenzen und Reprints

ABSTRACT

A second-generation recombinant factor VIII molecule was developed with an albumin-free formulation. In this modified form of factor VIII, the N- and C-terminal sections of the B-domain are retained and fused at serine 743 and glutamine 1638, resulting in a B-domain deleted factor VIII protein known as ReFacto® (Genetics Institute, Andover, MA). Preclinical studies of ReFacto have focused on efficacy of the product for the hemophilia A patient population. The efficacy and pharmacokinetic profiles of ReFacto were similar to plasma-derived factor VIII in correcting the hemostatic defect of hemophilia A dogs. Both ReFacto and plasma-derived human factor VIII (Octonativ-M7®, Pharmacia, Stockholm, Sweden) were found to associate with von Willebrand factor (vWF) after infusion into hemophilia A dogs as demonstrated by size exclusion chromatography. Infusion of either ReFacto or Octonativ-M7 quickly corrected factor VIII coagulant activity (FVIIIc), whole blood clotting time (WBCT), and activated partial thromboplastin time (aPTT). No obvious differences were seen between ReFacto and Octonativ-M7. Both ReFacto and Octonativ-M7 treatment reduced secondary bleeding time to less than 6 minutes. The clearance was faster and the volume of distribution at steady state was larger for plasma-derived factor VIII compared with ReFacto. The half-life was similar between Octonativ-M7 and ReFacto. These data predict that ReFacto will be effective in correcting human factor VIII deficiency states.

KEYWORDS

Hemophilia - recombinant factor VIII - B-domain deleted - canine - albumin free

REFERENCES

  • 1 Toole J J, Knopf J L, Wozney J M. Molecular cloning of a cDNA encoding human antihaemophilic factor.  Nature . 1984;  312 342-347
    CrossrefPubMedGoogle Scholar
  • 2 Poustka A, Dietrich A, Langenstein G. Physical map of human Xq27-qter: localizing the region of the fragile x mutation.  Proc Natl Acad Sci USA . 1991;  88 8302-8306
    PubMedGoogle Scholar
  • 3 Freije D, Schlessinger D. A 1.6-Mb contig of yeast artificial chromosomes around the human factor VIII gene reveals three regions homologous to probes for the DXS115 locus and two for the DXYS64 locus.  Am J Hum Genet . 1992;  51 66-80
    PubMedGoogle Scholar
  • 4 Wion K L, Kelly D, Summerfield A, Tuddenham E DG, Lawn R M. Distribution of factor VIII mRNA and antigen in human liver and other tissues.  Nature . 1985;  317 726-729
    CrossrefPubMedGoogle Scholar
  • 5 Hellman L, Smedsrod B, Sandberg H, Pettersson U. Secretion of coagulant factor VIII activity and antigen by in vitro cultivated rat liver sinusoidal endothelial cells.  Br J Haematol . 1989;  73 348-355
    PubMedGoogle Scholar
  • 6 Vehar G A, Keyt B, Eaton D. Structure of human factor VIII.  Nature . 1984;  312 337-342
    CrossrefPubMedGoogle Scholar
  • 7 Kane W H, Ichinose A, Hagen F S, Davie E W. Cloning of cDNA's coding for the heavy chain region of human Factor V, a blood coagulation factor with four types of internal repeats.  Biochemistry . 1987;  26 6508-6514
    CrossrefPubMedGoogle Scholar
  • 8 Andersson L-O, Forsman N, Huang K. Isolation and characterization of human factor VIII: molecular forms in commercial factor VIII concentrate, cryoprecipitate, and plasma.  Proc Natl Acad Sci USA . 1986;  83 2979-2983
    PubMedGoogle Scholar
  • 9 Brinkhous K M, Sandberg H, Garris J B. Purified human factor VIII procoagulant protein: comparative hemostatic response after infusions into hemophilia and von Willebrand disease dogs.  Proc Natl Acad Sci USA . 1985;  82 8752-8756
    PubMedGoogle Scholar
  • 10 Sandberg H, Almstedt A, Brandt J. Structural and functional characteristics of the B-domain-deleted recombinant factor VIII protein, r-VIII SQ.  Thromb Haemost . 2001;  85 93-100
    PubMedGoogle Scholar
  • 11 Triplett D A, Smith C. Routine testing in the coagulation laboratory. In:Triplett DA, ed. Laboratory Evaluation of Coagulation.  Chicago, IL: American Society of Clinical Pathologists Press 1982: 27-51
    Google Scholar
  • 12 Beard J, Savidge G F. Clinical and laboratory assessment of patients with hemophilia. In: Seghatchian MJ, Savidge GF, eds. Factor VIII-von Willebrand Factor Volume II. Clinical Aspects of Deficiency States Boca Raton, FL: CRC Press 1989: 33-47
    Google Scholar
  • 13 Pool J G, Hershgold E J, Pappenhagen A R. High-potency antihaemophilic factor concentrate prepared from cryoglobulin precipitate.  Nature . 1964;  203 312
    PubMedGoogle Scholar
  • 14 Lind P, Larsson K, Spira J. Novel forms of B-domain-deleted recombinant factor VIII molecules. Constructions and biochemical characterization.  Eur J Biochem . 1995;  232 19-27
    CrossrefPubMedGoogle Scholar
  • 15 Osterberg T, Fatouros A, Mikaelsson M. Development of freeze-dried albumin-free formulation of recombinant factor VIII SQ.  Pharm Res . 1997;  14 892-898
    CrossrefPubMedGoogle Scholar
  • 16 Graham J B, Buckwalter J A, Hartley L J, Brinkhous K M. Canine hemophilia. Observations of the course, the clotting anomaly, and the effects of blood transfusions.  J Exp Med . 1949;  90 97-111
    CrossrefPubMedGoogle Scholar
  • 17 Brinkhous K M, Widlund L, Read M S. Pharmacokinetics and pharmacodynamics of a B-domain deleted recombinant factor VIII derivative, r-VIII SQ, in canine hemophilia (Abst).  Thromb Hemost . 1993;  69 852A
    PubMedGoogle Scholar